Buy Panovir (sofosbuvir/Velpatasvir) online, Buy Epclusa online

Panovir | Epclusa | Sofosbuvir+Velpatasvir 400 mg + 100 mg by Incepta Pharmaceuticals is used to treat chronic hepatitis C, a viral infection of the liver.

Panovir is alternative of Epclusa by Gilead Sciences. Panovir is manufactured by Incepta Pharmaceuticals, which is the biggest pharmaceutical company in Bangladesh.

Therapeutic Class

Hepatic viral infections (Hepatitis C)

Pharmacology

It is a fixed-dose combination tablet containing sofosbuvir and velpatasvir for oral administration. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor and velpatasvir is an NS5A inhibitor.

Dosage & Administration

The recommended dosage is one tablet (400 mg of Sofosbuvir and 100 mg of Velpatasvir) / Epclusa taken orally once daily. Recommended treatment regimen:

Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A): one tablet once daily for 12 weeks

Patients with decompensated cirrhosis (Child-Pugh B or C): one tablet once daily and Ribavirin for 12 weeks. The recommended dosage of Ribavirin is based on bodyweight (1000 mg/day for patients < 75 kg and 1200 mg/day for ≥ 75 kg, in two divided dose/day)

Interaction

Drugs may decrease the concentrations of sofosbuvir and/or velpatasvir: Antacids, H2-receptor antagonists, Proton-pump inhibitors etc.

Coadministration is not recommended with: topotecan, Carbamazepine, Phenytoin, Phenobarbital, Oxcarbazepine, Rifabutin, Rifampin, Rifapentine, efavirenz, Tipranavir, Ritonavir, Hypericum perforatum.

Coadministration of Sofosbuvir and Velpatasvir combination, with Rosuvastatin, Atorvastatin may significantly increase the concentration of Rosuvastatin, Atorvastatin.

Contraindications

Sofosbuvir, Velpatasvir / Epclusa and Ribavirin combination regimen is contraindicated in patients for whom Ribavirin is contraindicated.

Side Effects

The most common side effects of Epclusa combination include headache and tiredness. Treatment may result in slowing of the heart rate along with other symptoms when taken with amiodarone (a medicine used to treat certain heart problems).

Tiredness, headache, nausea, diarrhea, or difficulty sleeping may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as depression), unusual tiredness.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

Pregnancy & Lactation

No adequate human data are available to establish whether Sofosbuvir and Velpatasvir / Epclusa combination poses a risk to pregnancy outcomes. If Sofosbuvir and Velpatasvir / Epclusa combination administered with Ribavirin.

Precautions & Warnings

Serious symptomatic bradycardia may occur in patients taking amiodarone, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease.

Coadministration of amiodarone with Sofosbuvir and Velpatasvir combination is not recommended. In patients without alternative viable treatment options, cardiac monitoring is recommended.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: other liver problems (such as hepatitis B), diabetes.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Use in Special Populations

Renal impairment patient: No dosage recommendation can be given for patients with severe renal impairment (eGFR ≤30 mL/min/1.73 m²) or with ESRD, due to higher exposures of the predominant Epclusa metabolite.

Overdose Effects

If overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose includes monitoring of vital signs as well as observation of the clinical status of the patient.

Storage Conditions

Store in a cool and dry place (preferably below 30° C). Keep out of reach of children.